Maternal iron supplementation in pregnancy and asthma in the offspring: follow-up of a randomised trial in Finland by Shaheen, Seif O. et al.
1 
 
Maternal iron supplementation in pregnancy and asthma in the offspring: follow-up of 
a randomised trial in Finland 
Seif O Shaheen1, Mika Gissler2,3, Graham Devereux4, Maijaliisa Erkkola5, Tarja I Kinnunen6, 
Harry Mcardle7, Aziz Sheikh8, Elina Hemminki2, Bright I Nwaru6,8-10. 
1Institute of Population Health Sciences, Barts and The London School of Medicine and 
Dentistry, London, Queen Mary University of London, UK. 
2Finnish Institute for Health and Welfare, Helsinki, Finland. 
3Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Stockholm, 
Sweden. 
4Liverpool School of Tropical Medicine, Liverpool, UK. 
5Department of Food and Nutrition, University of Helsinki, Helsinki, Finland. 
6Unit of Health Sciences, Faculty of Social Sciences, Tampere University, Tampere, Finland 
7Rowett Institute of Nutrition and Health, University of Aberdeen, Aberdeen, UK. 
8Asthma UK Centre for Applied Research, Usher Institute, University of Edinburgh, 
Edinburgh, UK. 
9Krefting Research Centre, Institute of Medicine, University of Gothenburg, Gothenburg, 
Sweden. 
10Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, 
Sweden 
 
Correspondence and reprint requests to: Prof Seif Shaheen, Institute of Population Health 
Sciences, Barts and The London School of Medicine and Dentistry, 58 Turner Street, London 
E1 2AB.  Email: s.shaheen@qmul.ac.uk  
Tel: +44 (0)20 7882 2480; Fax: +44 (0)20 7882 2552  
Word count: 1234 
2 
 
To the Editor: 
Evidence for the hypothesis that prenatal nutrition may influence the risk of childhood 
respiratory and atopic disorders has strengthened in recent years. For example, randomised 
controlled trials (RCTs) have suggested that maternal supplementation with vitamin D or fish 
oil in pregnancy could prevent early childhood wheezing and asthma in the offspring1;2. 
Another nutrient of interest is iron. Animal experiments have implicated iron in fetal airway 
development3. In two UK population-based birth cohorts, using different approaches, we 
have found evidence suggesting that lower maternal iron levels in pregnancy may increase 
the risk of wheezing, atopy and lower lung function in the offspring4-7. However, the 
possibility that unmeasured or residual confounding might explain these observational 
findings cannot be ruled out.  
To date, no RCT has been conducted to test whether prenatal iron is causally related to 
childhood respiratory and atopic outcomes, and whether increasing maternal iron levels in 
pregnancy could improve the respiratory health of offspring. Such a trial would be time-
consuming and expensive. A faster, more efficient, approach is to opportunistically use a 
previous RCT of iron supplementation in pregnancy, originally undertaken with other 
outcomes in mind, and to measure respiratory/allergic outcomes in the offspring8.  
We followed up the offspring of mothers who took part in a population-based, multi-centre, 
RCT of iron supplementation in pregnancy in Finland, using health register linkage to 
investigate whether prenatal iron influenced their risk of asthma. Full details of the trial have 
been reported previously9-13. Pregnant women were recruited during 1985-1986, and 2,944 
women were initially randomised, in each of 27 centres, to routine versus selective iron 
supplementation. After subsequent exclusions (e.g., twins) and miscarriages, 1,336 and 1,358 
women in each arm, respectively, were included in the original analyses of maternal and 
perinatal outcomes9;13. The routine iron (RI) group received 100 mg elemental iron/ day 
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throughout pregnancy, regardless of haemoglobin concentration, which was usual care in 
Finland at the time. The selective iron (SI) group received 50 mg elemental iron twice a day, 
but only if women were diagnosed as anaemic; this continued for two months or until their 
haemoglobin increased to 110 g/L10;11;13.  Compliance as reported by the mothers was good10. 
Haematocrit was measured at 12, 20, 28, and 36 weeks gestation, and information was 
collected on maternal factors, gestational age and weight at birth, and sex of child.   
Using unique personal identification numbers assigned to all Finnish residents, the RCT data 
were linked to national registers to ascertain the asthma status of the offspring of participating 
mothers. An asthma diagnosis was defined if an individual was found in the Register for the 
right to special reimbursement of medication and in the Register of reimbursed medication, 
maintained by the Social Insurance Institution (SII), and also had purchased asthma 
medication according to the Drug Prescription Register (Anatomical Therapeutic Chemical 
R03). To be eligible for the special reimbursement for purchase of asthma medication, a 
physician had to sign a certificate confirming an asthma diagnosis and the need for long-term 
treatment. Given that the registration for reimbursed medication started in 1995, an asthma 
diagnosis was only ascertained between 10-32 years of age. Additionally, using the inpatient 
admissions register, maintained since 1967 by the Finnish Institute for Health and Welfare, 
Helsinki, we defined first asthma admission (primary or secondary reason for admission) 
using the International Classification of Diseases (ICD) codes: ICD-8 (4930A, 4930B, 
4931B, 4939X) up to 1995; ICD-9 (J45-J46) between 1996 and 2017. Researchers abstracting 
these data were blind to treatment allocation. We analysed associations between trial arm and 
asthma diagnosis based on the SII reimbursement data (primary outcome) and asthma 
admissions (secondary outcome) using random-effects models (multilevel mixed-effects 
generalised linear model for the former, and multilevel mixed-effects survival model for the 
latter outcome). This allowed effects to vary between trial centres, given that randomisation 
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was stratified by centre14. Risk ratios and hazard ratios, respectively, were adjusted for 
prognostic factors known to be associated with childhood asthma risk, namely, maternal 
factors (age, pre-pregnancy body mass index, smoking and asthma) and sex of child, in order 
to increase statistical power15. Analyses were by intention-to-treat, using Stata version 15 
(StataCorp, College Station, TX, USA).  
Of the 2,694 women included in the original trial analysis, 2,666 (99%) were included in our 
follow-up analysis (1,320 in the RI arm and 1,346 in the SI arm). The Figure shows mean 
haematocrit in pregnancy by gestational age and trial arm. In the last two months of 
pregnancy, haematocrit increased substantially more in the RI group than in the SI group 
(difference at 36 weeks gestation P<0.001). There was no imbalance between trial arms in 
most background characteristics, but mothers in the RI arm were more likely to be 
underweight.  
During the follow-up period, there were 74 individuals with doctor-diagnosed asthma based 
on the SII data, and 138 first-time hospital admissions for asthma. Compared to offspring in 
the SI arm, those in the RI arm had a significant reduction in risk of asthma diagnosis 
(adjusted Risk Ratio 0.58 (95% CI: 0.35 to 0.96), P=0.033) and a non-significant reduction in 
risk of asthma admissions (adjusted Hazard Ratio 0.86 (0.61 to 1.22), P=0.41). As there was a 
minor reduction in the prevalence of premature birth in the RI group compared to the SI 
group, we repeated the analyses with further adjustment for gestational age at birth, but this 
did not alter the risk estimates.  
This study has a number of strengths. First, the association between routine iron 
supplementation in pregnancy and reduced risk of asthma diagnosis in the offspring is 
unlikely to be confounded, given that the intervention was randomised. Second, the increase 
in haematocrit in mothers receiving routine supplementation, which was not seen in the 
selective supplementation group, confirms compliance with supplementation, suggesting that 
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prenatal iron status is likely to have been significantly higher in the former group during the 
latter stages of pregnancy. With respect to asthma ascertainment, individuals identified in the 
reimbursement register are likely to represent the most severe asthma cases, given the strict 
criteria for reimbursement eligibility, so mild cases may not have been identified. Also, as the 
reimbursed medication register did not start until 1995, we could not ascertain an asthma 
diagnosis until the offspring were 10 years old, hence some cases under that age may not 
have been identified unless their condition persisted beyond that age. This limited our ability 
to assess the effect of iron supplementation on the incidence of early onset of disease, when 
most wheeze and asthma begins. In our experience, those admitted with ‘asthma’ to hospital 
are likely to include some individuals with acute infective episodes e.g. acute bronchitis, in 
whom a firm diagnosis of asthma is not confirmed subsequently. We therefore believe that 
ascertainment of an asthma diagnosis using the reimbursement register will have led to less 
misclassification of asthma, compared to asthma ascertained using the admissions register, 
and this may explain the stronger findings for the former asthma outcome. On the other hand, 
we acknowledge that the reimbursement register approach will have led to under-
ascertainment of mild cases and asthma beginning before 10 years of age. Importantly 
though, any misclassification of asthma is likely to be random (non-differential) with respect 
to trial arm, and this would tend to lead to an underestimation of effect. We also acknowledge 
that a trial comparing routine prenatal iron supplementation versus placebo would have 
enabled a more powerful test of our hypothesis; if the effects on asthma risk are causal we 
would expect such a trial to produce a larger effect than we observed in our study comparing 
two supplementation regimes. Whilst maternal iron deficiency is associated with lower birth 
weight and prematurity16, which are both risk factors for asthma, there was little impact of 
routine versus selective supplementation on these perinatal outcomes in this trial. Hence, they 
did not appear to mediate the reduction in risk of asthma associated with routine iron 
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supplementation. We speculate that improving prenatal iron status may have reduced the risk 
of more severe asthma by optimising airway growth. 
In conclusion, these findings suggest that routine iron supplementation may reduce the risk of 
asthma in the offspring, and could therefore offer a potential primary prevention strategy.  
Additional robust, randomised evidence from a low- or middle-income setting, where iron 
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